Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations-Reference-Cited by-同舟云学术

Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations

Published:2006 Issue:9 Volume:21 Page:1384-1395
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Sato Kenichi,Hatano Taku,Yamashiro Kazuo,Kagohashi Maki,Nishioka Kenya,Izawa Nana,Mochizuki Hideki,Hattori Nobutaka,Mori Hideo,Mizuno Yoshikuni,

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Reference48 articles.

1. Criteria for diagnosing Parkinson's disease

2. Adverse effects of levodopa. In: , editors. The Scientific Basis for the Treatment of Parkinson's Disease. Carnforth: Parthenon Publishing Group; 1992. p 89–112.

3. Immediate-release and controlled-release carbidopa/levodopa in PD : A 5-year randomized multicenter study

4. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: Role of early treatment and disease progression

5. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antagonism of metabotropic glutamate receptor type 5 prevents levodopa‐induced dyskinesia development in a male rat model of Parkinson's disease: Electrophysiological evidence;Journal of Neuroscience Research;2024-03

2. The incidence of deep venous thrombosis in Parkinson’s disease;Neurological Research;2023-09-12

3. Associations between non-motor symptoms and patient characteristics in Parkinson’s disease: a multicenter cross-sectional study;Frontiers in Aging Neuroscience;2023-09-06

4. Clinical and Non-Clinical Cardiovascular Disease Associated Pathologies in Parkinson’s Disease;International Journal of Molecular Sciences;2023-08-09

5. Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review;PharmacoEconomics;2023-06-21